Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Appoints Three to Management Positions

MANCHESTER, NH--(Marketwired - Dec 10, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex...
December 04, 2013 12:47 ET | Source: Boston Therapeutics

Boston Therapeutics Appoints Conroy Chi-Heng Cheng and S. Colin Neill to Board of Directors

MANCHESTER, NH--(Marketwired - Dec 4, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using...
November 18, 2013 07:38 ET | Source: Boston Therapeutics

Boston Therapeutics Presents at the Elsevier Therapeutic Area Partnerships 2013 Conference in Boston on November 19

MANCHESTER, NH--(Marketwired - Nov 18, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex...
November 14, 2013 07:05 ET | Source: Boston Therapeutics

Boston Therapeutics Exhibits at Obesity Week 2013 Conference

MANCHESTER, NH--(Marketwired - Nov 14, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovator developer of drugs that address diabetes using complex...
November 13, 2013 16:05 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Corporate Update and Financial Results for the Third Quarter and Nine Months Ended September 30, 2013

MANCHESTER, NH--(Marketwired - Nov 13, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovator of drugs that address diabetes using complex...
November 12, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Enrolls Patients With Type 2 Diabetes in a Phase IIb Clinical Trial With PAZ320

MANCHESTER, NH--(Marketwired - Nov 12, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovator in designing drugs that address diabetes using complex...
October 16, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics to Present at the Livingston Securities Advanced and Nano Life Sciences Summit

MANCHESTER, NH--(Marketwired - Oct 16, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of drugs that address diabetes using complex...
October 15, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Initiates Research Study on PAZ320 at University of Minnesota

MANCHESTER, NH--(Marketwired - Oct 15, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of drugs based on complex carbohydrate chemistry to treat...
October 03, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Closes $5.3 Million in Private Placement of Common Stock and Warrants

MANCHESTER, NH--(Marketwired - Oct 3, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of drugs based on complex carbohydrate chemistry to treat...
September 09, 2013 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Closes on Approximately $3.5 Million in Private Placement of Common Stock and Warrants

MANCHESTER, NH--(Marketwired - Sep 9, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of drugs based on complex carbohydrate chemistry to treat...